94. Primary sclerosing cholangitis Clinical trials / Disease details
Clinical trials : 148 / Drugs : 118 - (DrugBank : 39) / Drug target genes : 18 - Drug target pathways : 141
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05642468 (ClinicalTrials.gov) | January 23, 2023 | 23/11/2022 | Safety and Tolerability of A3907 in Primary Sclerosing Cholangitis | An Open Label, Phase 2 Study to Evaluate the Effect of A3907 on Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Adults With Primary Sclerosing Cholangitis (PSC) | Primary Sclerosing Cholangitis | Drug: A3907 | Albireo | NULL | Recruiting | 18 Years | 65 Years | All | 12 | Phase 2 | France;Italy;Spain |